Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of the First-line Therapy of T-cell Lymphomas
NCT07258680Phase 3Enrolling by invitation
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
- Start
- Oct 2013
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 3 trial of brentuximab vedotin in peripheral T-cell lymphoma (PTCL), sponsored by N.N. Petrov National Medical Research Center of Oncology. Started Oct 2013; status: enrolling by invitation.
02
Drugs
brentuximab vedotin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07258680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07258680.